MRTX1133 RESISTANCE - AN OVERVIEW

The identification of KRASG12C inhibitors has reignited desire in targeting RAS proteins. This work describes the invention in the KRASG12D-specific inhibitor MRTX1133 and demonstrates the feasibility of potently and selectively focusing on this oncogenic variant.One more probable benefit of combining KRAS inhibitors and checkpoint inhibitors is th